title: Comparison between ulinastatin and nafamostat for prevention of post-endoscopic retrograde cholangiopancreatography complications: a prospective, randomized trial.
abstract: OBJECTIVE
  Pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP). The aim of this prospective trial was to compare the effect of ulinastatin and nafamostat on the prophylaxis of post-ERCP complications.
  
  
  METHODS
  A total of 159 patients who underwent ERCP were divided into ulinastatin (n = 53), nafamostat (n = 53) and control (n = 53) groups. Each patient received ulinastatin (150,000 units), nafamostat (20 mg), or placebo from 2-4 h before ERCP to 6-8 h after ERCP. The primary endpoint was the incidence of PEP, and the secondary endpoints were the incidence of post-ERCP hyperamylasemia, hyperlipasemia and abdominal pain.
  
  
  RESULTS
  The overall incidence of PEP was 6.3% (10/159) and no significant differences were observed between ulinastatin and nafamostat groups in terms of the incidences of PEP (1.9% and 3.8%, P = 0.560), hyperamylasemia, hyperlipasemia, and abdominal pain, although these were significantly lower than those of the control group (P < 0.001).
  
  
  CONCLUSIONS
  There was no significant difference for preventing PEP between ulinastatin and nafamostat and both drugs were efficacious for preventing post-ERCP complications.
authors: Division of Gastroenterology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
authors: Ji Young
authors: JY
authors: Park
authors: Division of Gastroenterology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea. Electronic address: drjtj@paik.ac.kr.
authors: Tae Joo
authors: TJ
authors: Jeon
authors: Division of Gastroenterology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
authors: Mi Won
authors: MW
authors: Hwang
authors: Division of Gastroenterology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
authors: Dong Hyun
authors: DH
authors: Sinn
authors: Division of Gastroenterology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
authors: Tae-Hoon
authors: TH
authors: Oh
authors: Division of Gastroenterology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
authors: Won Chang
authors: WC
authors: Shin
authors: Division of Gastroenterology, Department of Internal Medicine, Inje University Sanggye Paik Hospital, Seoul, Republic of Korea.
authors: Won-Choong
authors: WC
authors: Choi
mesh_terms: D000328:Adult; D000368:Aged; D001550:Benzamidines; D002760:Cholangiopancreatography, Endoscopic Retrograde / Q000009:adverse effects*; D005260:Female; D006023:Glycoproteins / Q000627:therapeutic use*; D006146:Guanidines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000150:complications / Q000601:surgery*; D011183:Postoperative Complications / Q000517:prevention & control*; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000627:therapeutic use*
chemical_list: D001550:Benzamidines; D006023:Glycoproteins; D006146:Guanidines; D011480:Protease Inhibitors; C028665:urinastatin; C032855:nafamostat
keywords: Endoscopic retrograde cholangiopancreatography; Nafamostat; Pancreatitis; Post-endoscopic retrograde cholangiopancreatography complications; Post-endoscopic retrograde cholangiopancreatography pancreatitis; Ulinastatin